FDA Brief

Warning letters Drugs

FDA warning letter to

Miami University Department of Chemistry and Biochemistry

High riskIssued Apr 20, 2022Posted May 3, 2022Pharmaceutical Quality Operations Division III

Miami University contract testing lab falsified heparin API test data and lacked CGMP controls.

What happened

The FDA inspected the contract testing laboratory at Miami University from November 1 to November 5, 2021. The FDA found that a student analyst had entered arbitrary values for sample, spike, and correlation in testing data from about 2018 to 2021, and that computerized systems had shared logins, an uncontrolled results folder, no audit trail, and no backup. The FDA also found the lab lacked an adequate quality unit and documented CGMP training for faculty and graduate students who performed testing.

What FDA found

  1. The lab did not control its computerized systems, allowing unauthorized access or changes, including a shared master login, an uncontrolled results folder, no audit trail, unvalidated software, and no backup of raw data.

    FD&C Act section 501(a)(2)(B), 21 U.S.C. 351(a)(2)(B)
  2. An analyst entered arbitrary values for sample, spike, and correlation in testing data from about 2018 to 2021, and the raw data had not been reviewed since CGMP testing began.

    FD&C Act section 501(a)(2)(B), 21 U.S.C. 351(a)(2)(B)
  3. The lab did not have an adequate quality unit to oversee CGMP testing, and many procedures were created only after FDA contacted the firm.

    FD&C Act section 501(a)(2)(B), 21 U.S.C. 351(a)(2)(B)
  4. The lab did not show that faculty and graduate students performing CGMP testing were adequately trained, and training procedures were created about a week before the inspection.

    FD&C Act section 501(a)(2)(B), 21 U.S.C. 351(a)(2)(B)
  5. The Excel spreadsheet used to calculate spike recovery and final results was uncontrolled, sample reprocessing was not documented, and peaks in analyses were chosen without an established procedure.

    FD&C Act section 501(a)(2)(B), 21 U.S.C. 351(a)(2)(B)

What FDA wants

FDA tells the firm to respond in writing within 15 working days with a comprehensive data integrity investigation, risk assessment, corrective action plan, quality unit remediation, and lab training assessment. FDA also asks the firm to clarify whether it will resume drug testing and to notify FDA before resuming operations.

Who should pay attention

  • heparin API and drug product makers using contract labs
  • academic or contract testing labs performing CGMP work
  • quality units relying on outside labs for release testing

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Pritam International Private Limited

    Pritam International, an Indian OTC drug maker, was cited for CGMP violations, falsified lab data, unsafe color additive, and DEG/EG testing gaps.

    High risk
  3. Conroe Welding Supply, Inc.

    FDA warns Conroe Welding Supply over medical oxygen manufacturing failures, including untested batches and a container with 99% (b)(4).

    High risk
  4. SnugZ USA, Inc.

    SnugZ USA, an OTC drug maker in West Jordan, Utah, was cited for releasing drugs after retesting failed batches until they passed.

    High risk